Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe

Gábor Holló, Ulrich Thelen, Miguel A. Teus, Luciano Quaranta, Sylvia Ferkova, Nikola Babić, Marta Misiuk-Hojlo, Dimitrios G. Mikropoulos, Bartlomiej J. Kaluzny, Vassilios Kozobolis, Ingrida Januleviciene, Péter Kóthy, Cristina Camara, Andrea Russo, Patrycja Krzyzanowska-Berkowska, Iwona Cieślińska, Jeanette A. Stewart, Michael S. Kristoffersen, Lindsay A. Nelson, William C. Stewart

Research output: Article

6 Citations (Scopus)

Abstract

Purpose: To determine the direct costs of therapy over 5 years of a European monotherapy cohort begun on a prostaglandin (PTG) versus timolol in patients with primary open-angle glaucoma or ocular hypertension. Methods: A retrospective, multicenter, active-controlled, observational study. Data were abstracted for European patients treated as initial monotherapy in 1996 or afterward, with 5 years of available records. Results: This study included 271 patients (166 on a PTG and 105 on timolol at baseline). The average cost/month/patient over 5 years was $45.47±12.61 for PTG and $31.50±15.47 for timolol (P<0.001, based on German prices). After 5 years, although there was no difference in number of glaucoma medicines prescribed between groups (1.0 PTGs and 1.1 timolol, P=0.41), the timolol group demonstrated a higher intraocular pressure (17.7±2.9 vs. 16.5±3.0mm Hg, P<0.001), more medication changes (P=0.01), greater incidence of glaucomatous progression (P=0.04), and less patients persistent on original monotherapy (P<0.001) than the PTG cohort. Conclusions: Patients originally on timolol monotherapy have a lower cost of care over 5 years than those started on a PTG. However, timolol patients during follow-up may demonstrate a higher intraocular pressure, more progression, more medication changes, and lower persistency of the original monotherapy.

Original languageEnglish
Pages (from-to)493-498
Number of pages6
JournalJournal of Ocular Pharmacology and Therapeutics
Volume27
Issue number5
DOIs
Publication statusPublished - okt. 1 2011

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe'. Together they form a unique fingerprint.

  • Cite this

    Holló, G., Thelen, U., Teus, M. A., Quaranta, L., Ferkova, S., Babić, N., Misiuk-Hojlo, M., Mikropoulos, D. G., Kaluzny, B. J., Kozobolis, V., Januleviciene, I., Kóthy, P., Camara, C., Russo, A., Krzyzanowska-Berkowska, P., Cieślińska, I., Stewart, J. A., Kristoffersen, M. S., Nelson, L. A., & Stewart, W. C. (2011). Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. Journal of Ocular Pharmacology and Therapeutics, 27(5), 493-498. https://doi.org/10.1089/jop.2011.0051